Literature DB >> 2643666

Isolation of a yeast heptaglucoside that inhibits monocyte phagocytosis of zymosan particles.

M J Janusz1, K F Austen, J K Czop.   

Abstract

To isolate a unit ligand recognized by human monocyte beta-glucan receptors, acid-solubilized oligoglucosides were prepared by partial acid hydrolysis of purified yeast cell walls, gel filtered sequentially on Bio-Gel P-4 and P-2, derivatized with 2-aminopyridine, and separated by normal-phase HPLC. Ligand recognition was assessed by quantitating the effect of pretreatment with isolated materials on the capacities of adherent monocytes to phagocytose zymosan particles. Partial acid hydrolysis solubilized 23 +/- 4% (mean +/- SD; n = 7) of the cell wall glucans; at an input of 50 micrograms/ml, the solubilized products reduced the numbers of monocytes ingesting zymosan by an average of 44%. Gel filtration of acid-solubilized glucans on Bio-Gel P-4 revealed several peaks with phagocytosis-inhibiting activity, and fractions from the peak containing the smallest oligoglucosides, which accounted for 10 +/- 2% (mean +/- SD; n = 7) of the carbohydrate applied, were pooled. Further purification on Bio-Gel P-2 resolved this phagocytosis-inhibiting activity to a single peak that contained apparent heptaoses and accounted for 8 +/- 2% (mean +/- SD; n = 6) of the carbohydrate applied. At a concentration of 0.5 microgram/ml, the oligoglucosides pooled from the Bio-Gel P-4 and P-2 columns reduced the numbers of ingesting monocytes by 45 +/- 1% and 42 +/- 7% (mean +/- SD; n = 3), respectively. When derivatized with 2-aminopyridine, the oligoglucosides were resolved by HPLC to a number of peaks; a peak that eluted as an apparent heptaglucoside contained virtually all the inhibitory activity and accounted for only 6.6 +/- 0.7% (mean +/- SD, n = 7) of the carbohydrate applied. Gas chromatography analysis revealed only glucose and FAB-mass spectrometric analysis showed only heptaglucoside and no noncarbohydrate molecules. At a concentration of 1.6 ng/ml, the derivatized yeast heptaglucoside reduced the numbers of monocytes ingesting zymosan and glucan particles by 44 +/- 9% (mean +/- SD; n = 5) and 45 +/- 6% (n = 3), respectively. Thus, a heptaglucoside present in yeast cell walls is a unit ligand for human monocyte beta-glucan receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643666

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Evaluation of immunostimulatory activities of synthetic mannose-containing structures mimicking the β-(1->2)-linked cell wall mannans of Candida albicans.

Authors:  Kaarina Ranta; Kaisa Nieminen; Filip S Ekholm; Moniká Poláková; Mattias U Roslund; Tiina Saloranta; Reko Leino; Johannes Savolainen
Journal:  Clin Vaccine Immunol       Date:  2012-09-19

2.  Glucan receptor and zymosan-induced lysosomal enzyme secretion in macrophages.

Authors:  H Tapper; R Sundler
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

3.  Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease.

Authors:  Zsolt Barta; István Csípõ; Gábor G Szabó; Gyula Szegedi
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

4.  Plasma (1-->3)-beta-D-glucan and fungal antigenemia in patients with candidemia, aspergillosis, and cryptococcosis.

Authors:  T Miyazaki; S Kohno; K Mitsutake; S Maesaki; K Tanaka; N Ishikawa; K Hara
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

5.  Beta-1,2-linked oligomannosides from Candida albicans act as signals for tumor necrosis factor alpha production.

Authors:  T Jouault; G Lepage; A Bernigaud; P A Trinel; C Fradin; J M Wieruszeski; G Strecker; D Poulain
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

6.  Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes.

Authors:  J K Czop; J Kay
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.